Videos

Experts take a dive into available therapies and optimal treatment strategies for idiopathic inflammatory myopathies.

Theresa Human, PharmD, discusses RediTrex, a subcutaneous injection method of administering methotrexate.

Comprehensive insight on the treatment armamentarium for systemic lupus erythematous and nuances in selecting optimal therapy.

A brief review of idiopathic inflammatory myopathies, ranging from pathology to the goals of treatment.

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.

During this video interview, Dr. Jay Mehta talks about his approach to explaining such complex medical conditions and treatments to his pediatric patients and their families.

An overview of systemic lupus erythematous including possible causes, prevalence, symptomology, diagnosis, and the goals of therapy.

Expert rheumatologists share an overview of the characteristics of SARDs, covering rare disease status, quality of life, and associated comorbidities.

Dr. Mehta talks about rheumatologic testing, joint examinations, and the great relationships he gets to develop with his patients.

E Michael Lewiecki, MD, discusses his CCR West presentations entitled, “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?”

Dr. Mehta highlights some of the challenges that come with treating pediatric rheumatology patients and how he handles them.

In this video interview, Dr. Jay Mehta discusses his presentation on pediatric rheumatology for the American Association of Pediatrics Conference.

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

Sarah Stewart, PhD, discusses her study entitled "What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout."

Jason Kolfenbach, MD, discusses his CCR West presentations entitled “Common Eye Disorders in Rheumatology Clinic” and “Top Secrets in Rheumatology.”

Philip Conaghan, MBBS, PhD, discusses his presentation entitled, “Meaningful Improvements in WOMAC Pain and Physical Function in 3 Phase 3 Trials of Tanezumab in Patients With Moderate-to-Severe Osteoarthritis: A Responder Analysis.”

Susan Chrostowski, DNP, MS, APRN discusses her presentation, entitled “Demystifying Fibromyalgia for the Nurse and Advanced Practice Provider.”

The stigma surrounding gout has contributed to the general unease patients have about their condition.

Daniel Hernandez, MD, and Esteban Rivera discuss the study, “Social Listening: Factual vs. Misinformation YouTube Spanish-Language Rheumatoid Arthritis Videos,” presented at the 23rd Pan-American Conference of Rheumatology (PANLAR) 2021.

Dr. LaMoreaux believes that to treat gout in patients with proper medications and therapies, doctors must first establish trust and combat the stigma surrounding this painful form of arthritis.

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

Randall Cron, MD, PhD, discuss his lectures entitled, “The Immunology of COVID” and “The Role of Rheumatologists in COVID-19,” which will be presented at the Congress of Clinical Rheumatology.

Brian LaMoreaux, MD, MS, discusses the recent study entitled, "Improving outcomes for patients hospitalised with gout: a systematic review."

Dr. Blauvelt speaks on the results of the phase 3b Heads Up study, and the future of upadacitinib and dupilumab in atopic dermatitis management.

Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.

Leonard Calabrese, DO, discusses his findings entitled, “Applied Immunology to Autoimmune Diseases: COVID-19 as Immunology,” which was presented at the Rheumatology Nurses Society Conference.

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.